Effects of different potassium-lowering regimens on acute hyperkalemia in hemodialysis patients: a real-world, retrospective study.

Author: LiPing, LiYubao, LiangXianhui, WangPei, XingXiaoyang, YaoLan, ZhangFangxing

Paper Details 
Original Abstract of the Article :
BACKGROUND: Hyperkalemia is a common and potentially life-threatening electrolyte disorder in maintenance hemodialysis (MHD) patients. This study aimed to evaluate the efficacy and safety of potassium-lowering regimens during treatment of acute hyperkalemia in MHD patients. METHODS: This retrospect...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310460/

データ提供:米国国立医学図書館(NLM)

Effects of different potassium-lowering regimens on acute hyperkalemia in hemodialysis patients: a real-world, retrospective study

This real-world, retrospective study evaluates the efficacy and safety of different potassium-lowering regimens in hemodialysis (HD) patients experiencing acute hyperkalemia, a potentially life-threatening electrolyte imbalance. The study compared the effectiveness of four treatment groups: insulin and glucose (IG) intravenous administration, sodium polystyrene sulfonate (SPS), sodium zirconium cyclosilicate (SZC), and a combination of IG and SZC. The study found that SZC demonstrated similar potassium-lowering efficacy to IG intravenous administration at 2 hours, while offering greater convenience and a more favorable side-effect profile. The combination of IG and SZC was associated with the most significant decrease in serum potassium levels but also had a higher rate of symptomatic hypoglycemia. SPS was less effective than the other regimens and was associated with significant decreases in serum calcium and magnesium levels. The study provides valuable insights into the real-world effectiveness and safety of different potassium-lowering regimens in HD patients with acute hyperkalemia.

Optimizing potassium-lowering strategies in hemodialysis

This real-world study provides valuable insights into the real-world effectiveness and safety of different potassium-lowering regimens in HD patients with acute hyperkalemia. The study suggests that SZC is a promising treatment option, offering similar efficacy to IG intravenous administration while being more convenient and having a better side-effect profile.

Health implications and everyday applications

HD patients with acute hyperkalemia should consult with their healthcare provider about the most appropriate treatment option based on their individual medical history and potential risks and benefits.

Dr.Camel's Conclusion

Maintaining electrolyte balance is essential for maintaining health, and this study provides crucial guidance for clinicians treating hyperkalemia in HD patients. The findings highlight the importance of choosing the right potassium-lowering regimen for each patient, ensuring optimal outcomes and minimizing potential side effects.

Date :
  1. Date Completed 2022-07-27
  2. Date Revised 2022-08-10
Further Info :

Pubmed ID

35879718

DOI: Digital Object Identifier

PMC9310460

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.